Introduction
Acyclovir provides clinically effective antiviral treatment of first episode genital herpes when administered intravenously,' orally,23 or topically. 4 The results of two recent studies in Sheffield have suggested that the antiviral effect of oral acyclovir is clearly superior to that of topical acyclovir cream. 5 6 In the study published here the objective was to assess whether the concomitant use of acyclovir cream and oral acyclovir in patients suffering from first episode genital herpes conferred any more antiviral or clinical benefit than a placebo cream and oral acyclovir.
Patients and methods

STUDY POPULATION
Men and women aged 16 years or more who presented within six days of the onset of symptoms of first episode genital herpes to the department of genitourinary medicine, Royal Hallamshire Hospital, Sheffield, were eligible to enter the study. Patients were excluded if they had used other antiviral or immune stimulation treatment within the preceding seven days, if they had underlying immune deficiency, hepatic or renal disease, or were women who were not using a valid form of contraception. All entrants to the study gave informed consent.
The efficacy of each treatment was assessed by comparing the groups for the duration of viral shedding, duration of symptoms, and the times to healing of lesions. Each variable was analysed separately by fitting Cox's proportional hazards model with adjustments made for differences in response between male and female patients and between users and non-users of co-trimoxazole.
STUDY DESIGN
All patients were treated with oral acyclovir 200 mg four times daily for seven days. In addition they were given topical treatment with either 5% acyclovir cream or a matching placebo cream to be applied five times daily for seven days. The treatment was dispensed in a double blind fashion with separate stratification for the sex of the patient. Patients in both treatment groups were given identical advice regarding additional symptomatic treatment. Concomitant co-trimoxazole treatment was given to those patients considered to have secondarily infected lesions at presentation. PATIENT 
ASSESSMENTS, LABORATORY STUDIES, AND TOXICITY SCREENING
These were identical to those described in detail in previous studies.6 FOLLOW UP FOR RECURRENCE After their lesions had completely healed, patients were asked to report back to the clinic in the event of any subsequent recurrence and were seen routinely three and six months after entry.
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Efficacy of combined oral and topical acyclovir in first episode genital herpes STATISTICAL ANALYSIS the study. The differences for any of the assessed The treatment groups were compared for their demographic or clinical variables were not significant. demographic and clinical data at entry to the study. Table II shows the efficacy of each treatment for Possible differences between the groups in the women only and for men and women combined. The numbers of each sex, proportions infected with herpes mean (SD) duration of viral shedding, of a variety of simplex virus type 1, and proportions with true symptoms, and of the times to healing of lesions are primary infections, were assessed using the Fisher's given. Small numbers prevented satisfactory analysis Exact test. Differences in the severity of symptoms of the results for men only. were assessed using the Pearson X 2 test; in the mean
The only variable showing a statistically significant age of patients using the t test; in the duration of difference between the treatment groups was the symptoms and signs before presentation using the log shorter duration of itching in women treated with rank test. combined topical and oral acyclovir (p=0-04). 
